Sumitomo Mitsui Trust Group
CRSP icon

Sumitomo Mitsui Trust Group’s CRISPR Therapeutics CRSP Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$80.4M Sell
1,453,713
-267,021
-16% -$14.4M 0.05% 332
2026
Q2 		$93.8M Sell
1,720,734
-133,141
-7% -$7.02M 0.05% 313
2026
Q1 		$88.2M Sell
1,853,875
-104,236
-5% -$5.5M 0.06% 306
2025
Q4 		$103M Sell
1,958,111
-205,564
-10% -$12.3M 0.06% 283
2025
Q3 		$140M Sell
2,163,675
-251,163
-10% -$14.4M 0.08% 227
2025
Q2 		$117M Sell
2,414,838
-125,051
-5% -$4.84M 0.07% 253
2025
Q1 		$86.4M Sell
2,539,889
-205,787
-7% -$8.72M 0.06% 311
2024
Q4 		$108M Sell
2,745,676
-222,358
-7% -$10.5M 0.07% 262
2024
Q3 		$139M Sell
2,968,034
-183,480
-6% -$9.31M 0.1% 204
2024
Q2 		$170M Sell
3,151,514
-117,271
-4% -$6.78M 0.13% 161
2024
Q1 		$223M Sell
3,268,785
-100,977
-3% -$7.23M 0.15% 145
2023
Q4 		$211M Sell
3,369,762
-95,708
-3% -$5.29M 0.16% 145
2023
Q3 		$157M Sell
3,465,470
-67,887
-2% -$3.51M 0.13% 167
2023
Q2 		$198M Sell
3,533,357
-439,823
-11% -$25M 0.15% 141
2023
Q1 		$180M Sell
3,973,180
-33,296
-0.8% -$1.62M 0.13% 169
2022
Q4 		$163M Sell
4,006,476
-256,260
-6% -$13.6M 0.13% 182
2022
Q3 		$279M Sell
4,262,736
-321,362
-7% -$23.3M 0.23% 100
2022
Q2 		$279M Sell
4,584,098
-35,649
-0.8% -$2.1M 0.21% 98
2022
Q1 		$290M Buy
+4,619,747
New +$290M 0.19% 113

Other funds holding CRSP

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sumitomo Mitsui Trust Group's CRSP Position: Q3 2026 in Review

Sumitomo Mitsui Trust Group reduced its CRISPR Therapeutics (CRSP) stake by 16% in Q3 2026, selling an estimated $14.4M and leaving 1,453,713 shares worth $80.4M. The position accounts for 0.05% of the portfolio, ranked #332.

Sumitomo Mitsui Trust Group first reported a position in CRSP in Q1 2022 and has held it in 19 quarters since. The position peaked at $290M in Q1 2022. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Sumitomo Mitsui Trust Group held 1,453,713 shares of CRISPR Therapeutics worth $80.4M as of Q3 2026.
  • Sumitomo Mitsui Trust Group sold 267,021 CRISPR Therapeutics shares in Q3 2026, an estimated $14.4M.
  • CRISPR Therapeutics made up 0.05% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #332 holding.
  • Sumitomo Mitsui Trust Group first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Sumitomo Mitsui Trust Group's CRISPR Therapeutics position peaked at $290M in Q1 2022.
  • 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.